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 Our current therapeutic mental health paradigms have been unable to 
adequately handle the mental illness crisis we are facing. We ought to ‘use every tool in 
our toolbox’ to help individuals heal, and the tool we should be utilizing right now is 
Psilocybin. Although it is classified as a Schedule I drug, meaning that it is believed to 
have a high potential for abuse, no accepted medical uses, and a lack of safety when 
used under medical supervision, Psilocybin is not addictive and does not have a high 
potential for abuse when used safely under medical supervision. For these reasons 
alone, Psilocybin deserves a reclassification for therapeutic purposes. However, many 
individuals oppose Psilocybin-assisted psychotherapy on ethical grounds or due to 
societal concerns. These concerns include: a potential change in personal identity, a 
potential loss of human autonomy, issues of informed consent, safety, implications of 
potential increased recreational use, and distributive justice and fairness issues.  
Decriminalization, which is distinct from reclassification, means that individuals 
should not be incarcerated for the use of such plant medicines. This must happen first 
to stop racial and societal injustices from continuing as there are no inherently ‘good’ or 
‘bad’ drugs. Rather, these substances are simply chemicals that humans have 
developed relationships with. As is shown in this thesis, the ethical implications and 
risks of psychedelic medicine can be adequately addressed and balanced, and the 
benefits of Psilocybin as a healing tool far outweigh the risks. For these reasons, we are 
scientifically and ethically obligated to reschedule Psilocybin for therapeutic purposes. 





harness the healing power that is within us through the use of plant medicines, we need 
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y “Psychedelics are to the study of the mind what the microscope is to biology and 
the telescope is to astronomy.” – Dr. Stanislas Grof 
 
y “It’s a very salutary thing to realize that the rather dull universe in which most of 
us spend most of our time is not the only universe there is. I think it’s healthy that 
people should have this experience.” – Aldous Huxley 
 
y “Psychedelics are illegal not because a loving government is concerned that you 
may jump out of a third story window. Psychedelics are illegal because they 
dissolve opinion structures and culturally laid down models of behaviour and 
information processing. They open you up to the possibility that everything you 
know is wrong.” – Terrence McKenna 
 
y “We are sneaking psychedelics back into our society through research like the 
MDMA research that's going on, through the research for the use of marijuana for 
pain, through research with the dying [with Psilocybin], and ultimately we will do 
the same kind of stuff about alcoholism, about prison rehabilitation, so on. I 
mean, it’s obvious that psychedelics, properly used, have a behavior-change 
psychotherapeutic value. But from my point of view, that is all underusing the 
vehicle. The potential of the vehicle is sacramentally to take you out of the 
cultural constructs which you are part of a conspiracy in maintaining. And giving 
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Current State of Mental Health Illnesses and Treatments 
 
Mental health illnesses continue to skyrocket while the development of new 
psychiatric treatments has followed the opposite trend.1 According to the National 
Institute of Mental Health, tens of millions of people are affected by mental illnesses 
each year, and only half of these people receive treatment; nearly one in every five 
adults in the United States lives with a mental illness.2 Furthermore, mental health 
disorders are posing great economic challenges to health systems around the world, 
and the COVID-19 pandemic has only further exacerbated these challenges.3,4 There is 
an urgent need for a “radical change in the paradigm and practices of mental health 
care, including improving standards of clinician training, developing new research 
methods, and re-envisioning current models of mental health care delivery.”5 
Psychedelic medicine is exactly the radical change we need to incorporate into mental 
health care as a therapeutic tool. Psychedelics initially showed great promise as 
therapeutic tools in the 1940s and 1950s, but the counterculture movement and 
increased recreational use in the 1960s led to their classification as Schedule I drugs 
with the passage of the Controlled Substances Act (CSA) in 1970.6 A Schedule I 
substance is one that is believed to have a high potential for abuse, no accepted 
medical uses, and a lack of safety when used under medical supervision, according to 
the Drug Enforcement Administration.7 In the span of twenty-five years, psychedelics 





experimentation and closing the door to opportunities that psychedelics offer. However, 
recently, there has been a revival of psychedelic medicine as a model of mental health 





Being in the midst of a global renaissance of psychedelic research8 further calls 
for the reclassification of such substances. Current treatments for mental health 
ailments like depression, anxiety, post-traumatic stress disorder, and addiction are not 
meeting current needs, seeing as mental health disorders continue to stress our 
nation’s health care system. Therefore, we ought to, safely and under close supervision 
where necessary, ‘use every tool in our toolbox’ when it comes to combating this mental 
illness epidemic we are facing. Psychedelics are a very promising therapeutic tool to 
treat mental illnesses, especially because they only require a few high-dose sessions of 
treatment, rather than a lifelong dependence on medication or psychotherapy.8,9 It was 
not science that led to the passage of the CSA10, but since there have been new 
advances in science and technology and it has been more than fifty years since the 
CSA was passed, it is time to reconsider the scheduling of psychedelics. Currently, 
there has been quite a bit of research on Psilocybin specifically, so I will be using that 
as a case study of sorts. There are also some particular reasons why Psilocybin may be 





generalizable, the same ethical argument would apply to other serotonergic psychedelic 
substances as well.  
Psilocybin is currently a Schedule I drug, yet research has shown that Psilocybin 
does not have a high potential for abuse when used therapeutically, is not addictive, is 
rather medically useful, and has been shown to be safe when used under medical 
supervision in controlled settings.6,11–16 However, there are people who object to the use 
of Psilocybin, and psychedelics in general, on ethical grounds. There are two general 
categories of implications and risks that must be addressed: (1) issues with the 
Psilocybin experience itself and (2) societal issues resulting from reclassification. While 
these concerns are genuine, the ethical implications and risks that come with 
psychedelic psychotherapies can be safely balanced, and the benefits of using 
Psilocybin in clinical settings far outweigh the risks. Therefore, we are scientifically and 
ethically obligated to reschedule Psilocybin for therapeutic purposes. Human beings 
have been therapeutically and spiritually using these sorts of visionary substances for 
almost our entire existence.17 We need to create new ways of safely incorporating plant-
based medicines into our lives, and that starts with the reclassification of Psilocybin. 
 
V. Issues with the Psilocybin Experience Itself 
 
How Does Psilocybin Work? 
 
To begin, I will focus on issues with the Psilocybin experience itself which 





autonomy, (3) concerns regarding informed consent, and (4) safety concerns related to 
the potential for a ‘bad trip’. In order to understand the issues that people have with the 
Psilocybin experience, it is important to first briefly discuss how Psilocybin is believed to 
function. Psilocybin is a ‘classic’ psychedelic substance and the primary psychoactive 
compound found naturally in magic mushrooms.18 Psychedelics are mind-manifesting 
substances; the origin of the term ‘psychedelic’ comes from two words: psyche, 
meaning mind, and delis meaning to manifest. There are many psychedelic substances 
other than Psilocybin, such as mescaline found in various types of cacti, 
dimethyltryptamine (DMT) which is the substance in ayahuasca, d-lysergic acid 
diethylamide (LSD), and 3,4-methylaenedioxy-methamphetamine (MDMA) among 
others. As with LSD, the other ‘classic’ serotonergic psychedelic, Psilocybin primarily 
acts on the serotonin neurotransmitter system as an agonist of serotonin 2A receptors 
(5-HT2AR).19–21 Serotonin is a neurotransmitter that affects mood and emotions. 
Furthermore, the amygdala, which is considered the emotion center of the brain, has 
been seen to have decreased reactivity to negative emotional stimuli after 
administration of Psilocybin; it is believed that neural patterns break down as the 
connectivity between different parts of the brain becomes more diverse and dynamic.22 
This break down of neural patterns is related to the default mode network (DMN) in our 
brains. The DMN is a network of neural pathways that help us function in the world:  
As we mature, we learn to respond to life’s stimuli in a patterned way, developing 
habitual pathways of communication between brain regions, particularly those of 
the DMN. Over time, communication becomes confined to specific pathways, 





constrained paths of communication between brain regions that quite literally 
come to constitute our ‘default mode’ of operating in the world, coloring the way 
we perceive reality.23 
During illnesses like depression and addiction, the DMN becomes over-engaged with 
negative thoughts and cravings. However, it is believed that when the DMN stops being 
so over-engaged, it allows people to break free from destructive neural patterns that are 
implicated in various mental health illnesses.24 Psilocybin, and psychedelics in general, 
alter the DMN in profound ways that have very promising clinical applications.22,25,26 
According to Dr. Roland Griffiths, a leading expert on mood-altering drugs and the 
founder of the Johns Hopkins Center for Psychedelic and Consciousness Research, 
“under psychiatric conditions when there are network functions that are being 
mismanaged or not working very well, there’s this opportunity for global 
interconnectivity. And that resolves [and] perhaps [resets] some of these networks to 
more ‘healthy’ patterns”.27,28 Psilocybin in particular is more appealing to researchers 
than other serotonergic psychedelics like LSD because “its duration of action is about 6 
hours compared with LSD’s 10-12 hours, which makes it more manageable to work with 
in a clinical setting; and, unlike LSD, it does not have the same strong association with 
the counterculture of the 1960s.”24  
 
Personal Identity  
 
Regarding personal identity and the Psilocybin experience, a possible argument 





experience, effectively rendering myself a different person than I was before; I do not 
want to become a different person, especially if I am not able to stop the identity 
transformation partway through. This objection is indeed grounded in legitimate 
concerns, as many users of Psilocybin, and psychedelics in general, experience a 
sense of ‘ego-dissolution,’ which is related to feelings of increased unity with others and 
one’s surroundings.29–31 This can be considered a compromised sense of self, and 
researchers have shown that this is a key feature of the psychedelic experience.29 
However, it is not clear whether this experience actually makes one less oneself. I 
would even go as far as to argue that one may be more themself than ever while under 
the influence of psychedelics. As philosophers from the University of Adelaide in 
Australia describe it, “‘ego dissolution’ in the psychedelic experience is a window [to 
see] the nature of self-awareness.”32 Discussed earlier, the DMN, while allowing us to 
efficiently interact with our environments, also constrains us as we grow older.23 I posit 
that walls within our mind that are also part of this DMN are able to be broken down with 
the use of Psilocybin; we are able to grow out of the constrained box we became 
accustomed to living in, thereby putting ourselves more in touch with our personal 
identity.  
Even if you do not agree that psychedelic substances have the ability to put us in 
touch with our true identity and still object to the identity transformation, traditional 
psychotherapy already induces changes in personality and identity. We currently treat 
personality disorders with psychotherapy, definitively inducing changes in 
personality.33,34 The use of Psilocybin is just a form of medication-assisted 





and culture surrounding Psilocybin, and psychedelics in general, are hindering its 
acceptance as a therapeutic tool. This combination of a psychedelic drug and 
psychotherapy can be thought of as the induction of an experience with extremely 
positive long-term mental health consequences, rather than daily neurochemical 
corrections in the brain.1 Rather than leading to a lifetime need for repeated 
administration of other drugs (SSRIs, antipsychotics, etc.) or therapy, one to two high 
dose sessions of Psilocybin, intertwined with psychotherapy, results in long-lasting 
changes.13-15 According to psychologist Duncan Blewett, psychedelics offer a superior 
form of therapy because they “aide man in seeing himself, his values and his behaviour 
in [a] new perspective; in freeing himself from disadvantageous patterns of thought and 
action” one is able to heal.8 By using this ‘companions in guilt’ argument (i.e. showing 
that we do not morally object to a similar practice we already engage in), Psilocybin-
assisted psychotherapy should be treated as other medication-assisted 
psychotherapies. 
However, even if people accept this ‘companions in guilt’ argument, they might 
still object to the intense nature of the identity transformation. They would argue that this 
identity transformation, while similar to that experienced during typical psychotherapy, 
happens very rapidly during a Psilocybin experience. There is a much more rapid 
change in personal identity that the individual might not have as much control over, 
whereas in typical therapy it is more gradual as one works through things and goes 
back and forth with the therapist. This is a legitimate objection because the psychedelic 
experience is of a much shorter duration and higher intensity than traditional 





must be understood that doctors are not simply giving this drug to patients and sending 
them on their way once they are done journeying. There are several pre-experience 
sessions and post-experience sessions, usually called preparatory and integrative 
psychotherapy, respectively.1,12,16,20 It is crucial to understand that this is another form 
of medication-assisted psychotherapy, and the main transformation occurs once you 
have learned how to integrate your new knowledge into your everyday life after the 
experience. Furthermore, not only is a change in identity already part of the goal with 
current mental health therapies, but this change is also one desired by the patient in 
order to become more aligned with their true self. It can be understood as a form of 
medication-assisted therapy during which a patient is able to seek and understand their 
true self that has been boxed out by the DMN. Psychedelic medicine is especially 
helpful for individuals who have been unable to heal with other traditional 
psychotherapeutic approaches. 
 
Human Autonomy  
 
Moreover, this brain blast, or restorative burst, might be very necessary for 
patients to help them heal. A very closely related concept to personal identity is human 
autonomy; when one is able to autonomously make choices, they do so in ways that 
align with their true identity. I argue that Psilocybin would actually boost the autonomy of 
individuals afflicted with mental health illnesses. We already boost autonomy for 
individuals affected by opioid use disorder when we prescribe them methadone. They 





cravings.35 When one is able to control their cravings, they regain autonomy.36 Similarly, 
if someone presents to a hospital experiencing a manic/psychotic episode, we do not 
treat them as having autonomy until they are medicated. Psilocybin is just another 
substance that can be used as a tool to help individuals with severe mental illnesses 
regain their sense of autonomy; and it is an especially effective tool for developing 
autonomy as it need not be taken as a daily prescription medication. Sometimes when 
we give people exogenous chemical compounds that feel like a blast to the brain, we 
are actually calming down certain harmful patterns of thinking, which allows the 
individual to regain control of their life. I would even go so far as to argue that Psilocybin 
is better to help people regain autonomy than other drugs due to the ability for long-
lasting effects after just a few administrations. In contrast to prevailing trends in 
psychopharmacological treatments that rely on long-term chemical consumption, 
psychedelic therapies involve short, intense treatment sessions preceded and followed 
by psychotherapy sessions. While other methods frequently lead to a physical and/or 
psychological dependence on chronic pharmacotherapy, psychedelic therapies avoid 
such dependence and truly help the patient in resurrecting self-control.8  
Some may argue that due to the ‘ego-dissolution’ they may experience, they are 
losing autonomy during the brief period of the Psilocybin experience. However, I believe 
that the Psilocybin experience is actually an expansion of autonomy rather than a loss. 
If Psilocybin has the proposed effects on the DMN, then I posit that one is more 
autonomous during and after the Psilocybin experience. The DMN constricts one’s 
thoughts and actions; it is our ‘default’ way of interacting with the world. For people with 





ingrained in their DMN that they aren’t autonomously thinking about those 
actions/choices anymore. By downregulating or temporarily turning off the DMN, one is 
capable of expanding their autonomy by breaking away from any default modes to 
which they may have grown accustomed, such as depressive thoughts, addictions, etc. 
Psilocybin allows one to deconstruct the deeply ingrained systems of the mind, 
ultimately leading to freedom of the self and the ability to make truly autonomous 
decisions. Furthermore, the Psilocybin experience is one in which the person is looking 
introspectively within themselves, as their own guide. The trained professionals present 
are there only to help if the patient needs them as a safety net. As Dr. Matthew Johnson 
analogized, the patient is like the astronaut and the doctors are like ground control.37 
This further allows the patient to be in charge of their experience rather than having a 
psychotherapist or other medications control them; Psilocybin puts patients in a position 
to heal themselves.  
Drawing upon the work of the philosopher Harry Frankfurt, I posit that Psilocybin 
can enable people to fulfill their second-order desires, or higher-order desires. Frankfurt 
describes humans as having first-order desires and second-order desires.38 A first-order 
desire is the initial desire to perform a certain action, whereas a second-order desire is 
a desire about a desire.38 Using the example of heroin addiction, the first-order desire of 
an individual who is addicted to heroin would be to fulfill their craving and seek out the 
drug. However, if they are seeking treatment, they do not want to be addicted. That is 
their second-order desire, and there is a conflict between their desires. Psilocybin 
allows one to take control over their first-order desires in order to truly manifest their 





Individuals are able to more autonomously live their lives as they make choices that 
align with their higher-order desires. These autonomy concerns can be further 
addressed by upholding the bioethical principle of respect for persons, a consideration 
that was taken into account in the ethical framework for psychedelic research that I will 
discuss in the following section. All in all, the Psilocybin experience enables patients to 
truly understand their personal identity and expand their autonomy in ways that they 




            Is truly informed consent even possible given the subjectivity of the experience 
and how little we know about these substances? Also, if someone starts having a ‘bad 
trip,’ they cannot withdraw consent and leave part-way through the experience. They 
are stuck with the consent they gave at the beginning of the experience. Moreover, with 
the ‘ego dissolution’ one may experience, they might want to change their consent 
during the experience. This is a genuine concern due to the mind-altering 
characteristics of Psilocybin; however, the subjectivity and unknown-ness of the 
experience can be balanced with enhanced informed consent. William Smith and 
Dominic Sisti from the Departments of Psychiatry and Medical Ethics and Health Policy, 
respectively, at the University of Pennsylvania Perelman School of Medicine have 
developed suggested disclosure information and questions for consent to Psilocybin 
that I believe are quite comprehensive and afford doctors the ability to obtain adequate 





unexpected for patients that they posit are: shifts in values and personality, mental 
health risks, and therapeutic touch (ethical implications of potentially holding a patient’s 
hand to comfort them during their experience).39 The concepts that need to be fully 
disclosed as part of the enhanced consent process include: information about the 
experience, information about potential long-term changes, information about the 
mechanism, therapeutic touch, and questions for subjects’ reflection.39 If all of these 
topics are discussed with the patient and the patient understands that this is a highly 
subjective experience and, at the end of the day, there may be things that happen that 
we did not initially know would happen, this is sufficient informed consent for one to 
decide to undergo this treatment.  
            The Multidisciplinary Association for Psychedelic Studies (MAPS), a non-profit 
leader in psychedelic research since 1986, has been at the forefront of many 
breakthroughs and debates when it comes to psychedelic medicine. MAPS, along with 
the MAPS Public Benefit Corporation (MPBC), have developed an ethical framework for 
psychedelic therapy research which I believe is acceptable. They have posited five 
principles and their applications to psychedelic research: (1) respect for persons, which 
calls for ensuring voluntariness, capacity, and informed consent, and conducting 
harm/benefit analyses that are justifiable for individual participants or their populations; 
(2) radical transparency, which calls for publishing research protocols, drug sourcing 
information, outcomes, ancillary data, and finances; (3) collaboration and open science, 
which calls for working in partnership with other research organizations, whether 
nonprofit or for-profit, to advance the science of psychedelics; (4) justice and fairness, 





in recruitment of participants, and benefit sharing and compassionate use; and (5) 
democratic deliberation, which calls for maintaining open dialogue with communities 
involved in research and providing regular educational programming for participants, 
advocates, and the broader community.40 As long as these principles are emphasized 
along with the enhanced informed consent, the Psilocybin experience is an ethically 
permissible treatment for severe mental health illnesses. 
 
Safety Concerns & ‘Bad Trips’ 
 
 Psilocybin, and other psychedelics as well, is most well-known for its 
psychological effects; it alters mood and perception in profound ways. “The feature that 
distinguishes the psychedelic agents from other classes of drug is their capacity reliably 
to induce states of altered perception, thought, and feeling that are not experienced 
otherwise except in dreams or at times of religious exaltation.”6 Yet, when it comes to 
any chemical substance, the physiological effects of the substance must be analyzed to 
ensure that consuming the substance is safe for the body. For decades, psychedelics 
have been portrayed as very dangerous drugs.6 However, Psilocybin is considered 
extremely physiologically safe, non-addictive, and has been used in therapeutic 
settings.6,11–16,41 A study at the Johns Hopkins University School of Medicine did find 
that Psilocybin dose-dependently caused delayed, transient headaches in healthy 
volunteers; however, Johnson et al. were clear to note that the headaches lasted no 





medical or otherwise. As these headaches were neither severe nor disabling, they 
“should not present a barrier to future Psilocybin research.”42  
Psychologically speaking, psychedelics put an individual in a vulnerable mental 
state. A psychedelic experience can be thought to be a non-specific amplifier of 
psychological content, both positive and negative. Psilocybin has the ability to put one in 
touch with trauma that may have been hidden deep within one’s mind, and which may 
be the root cause of their current mental health ailment. There is a risk of someone 
becoming re-traumatized as they confront their trauma, as well as experiencing other 
forms of psychological distress. This is what one might refer to when describing a ‘bad 
trip.’ However, the term ‘bad trip’ is actually quite misleading as this ‘bad’ experience 
can lead to positive outcomes.43 According to a survey study of positive and negative 
consequences of the psychedelic experience after ingesting Psilocybin mushrooms, 
84% of respondents reported benefiting from the so-called ‘bad trip.’44 The researchers 
found that the “incidence of risky behavior or enduring psychological distress is 
extremely low when Psilocybin is given in laboratory studies to screened, prepared, and 
supported [patients].”44 These realizations have caused a shift in the descriptive 
terminology; these experiences are now being called ‘challenging experiences,’ which 
acknowledges that, “when they’re handled well, as in the context of a clinical setting, 
they can lead to positive outcomes.”41 Furthermore, it has been hypothesized that the 
concept of a ‘bad trip’ was strategically used in government propaganda to promote 
public support of a prohibition of psychedelics.45 This conceptualization also justified 
interventions and regulations to remove these substances from the legal and medical 





process, Psilocybin can help individuals process this trauma in the vicinity of 
professionals. Rather than alleviating symptoms of a mental health illness, Psilocybin 
helps individuals confront the root cause and truly heal themselves. 
The risks that these challenging experiences may bring about are minimized if 
one is given the proper space in which to heal. This is where the concept of ‘set and 
setting’ is imperative to the safe use of Psilocybin for therapeutic purposes. The term, 
set and setting, that was initially coined by Harvard professor Timothy Leary, has now 
come to refer to the “psychological, social, and cultural parameters which shape the 
response to psychedelic drugs.”46 The set refers more to the psychological location, or 
mindset, that an individual has when going into an experience, and the setting refers 
more to the physical location that they are in. A safe set and setting must be 
emphasized in order to minimize any risks. Appropriate procedures for using 
psychedelics in clinical settings to minimize risk, proposed by Johnson et al., include:  
(1) the presence of two “monitors” with some medical knowledge, knowledge of 
[altered states of consciousness], and a degree of clinical sensitivity; (2) a 
physical environment that is safe, aesthetically pleasing, and comfortable; (3) 
careful subject preparation, including several meetings to establish rapport and 
trust with the monitors; (4) a detailed consent form and explanations of the study 
procedures, detailed discussions about the range of potential experiences, and a 
time of onset and duration of the effects; and (5) an available physician in the 
event of an untoward medical reaction.6,41 
People with certain underlying mental health conditions may have the additional risk of 





screened for in potential patients.41 There is a potential for long-term psychoses, such 
as hallucinogen persisting perception disorder, but this is very rare and the volunteer 
selection section of Johnson et al.’s guidelines are a key factor in minimizing risk.41  
Psychedelics are a very promising treatment for a variety of illnesses; however, 
the experience is quite intense and potentially risky – there is no doubting that. Not 
everyone plagued by a mental health illness should immediately look to Psilocybin and 
other psychedelics as treatment. However, in a controlled setting with properly trained 
and prepared monitors present, risks can be minimized so that this medicine can be 
used to battle the mental health crisis we are currently facing. There is always a risk 
versus reward analysis with any medication or treatment, and for Psilocybin, safety 
concerns are adequately addressed when it is used in clinical settings under 
supervision. 
 




When it comes to drugs, I assert that there is no such thing as a ‘good’ or ‘bad’ 
drug. The drugs themselves are not inherently ‘good’ or ‘bad’ substances; they are 
simply chemicals that we, as humans, have developed relationships with. It is the 
intention that people have going into their use of a drug, and the circumstances 
surrounding their drug use that dictate whether or not their outcome will tend to be 





for the stigmatization of certain groups of people, which is morally impermissible. Why 
do we as a society think that certain chemicals are better or worse than others? We are 
at the precipice of a social paradigm shift in which we can use plant medicines, such as 
Psilocybin, in a more culturally accepted way in order to help people heal. I believe we 
need some level of medicalization to validate these medicines and begin creating 
access, but we need to decriminalize first to not further the injustices that have been 
occurring since the illegalization of these plant medicines in 1970. 
Decriminalization needs to happen first to destigmatize Psilocybin and stop the 
criminalization of people for certain substances like cannabis and psychedelics and not 
others like alcohol and nicotine. Unfortunately, decriminalization is a whole other issue 
in and of itself, and truly requires more space that I am able to give it here. However, 
briefly, I will be drawing upon the works of Dustin Marlan and Mason Marks who have 
written about psychedelic decriminalization and social and legal issues, respectively. 
Dustin Marlan’s piece titled Beyond Cannabis: Psychedelic Decriminalization and Social 
Justice makes some convincing arguments for decriminalizing psychedelics on the 
basis of medical value, religious freedom, cognitive liberty, and identity politics.10 Marlan 
goes on to propose a way in which decriminalization may be more plausible, which I find 
quite interesting:  
…given the neurological changes in the brain caused by use of psychedelics, 
psychedelic law reform can also be conceptualized as a matter of neurodiversity 
– a recent claim to equality holding that neurological variations should be 
recognized and respected along with other human differences. [Marlan argues] 





as a matter of social justice, could lessen the stigma surrounding psychedelics 
and generate additional popular support for future decimalization efforts.10 
Marlan also discusses the work of Mason Marks, who further makes a convincing case 
for decriminalization. Marks, in his “comprehensive review of the social and legal 
obstacles to developing psychedelic medicines” explains how with “subtle modifications 
to state and federal drug law, psychedelics could be thoroughly studied and made 
available to patients under carefully controlled conditions.”47 Given how promising 
Psilocybin has proven to be as a treatment for various ailments of the mind6,11–16, it is 
crucial to move past the 1960s-era stigma surrounding psychedelics.41,47 Despite the 
promising results,  
…investigations into [the] therapeutic effects [of psychedelics] are often too slow, 
expensive, and infrequent. Legitimate medical research is hindered by the 
Schedule I status of [psychedelics]. Updating current regulations could reduce 
barriers to research and open up new alternatives to millions of patients who are 
nonresponsive to traditional therapies.47  
Decriminalization combats the issue of the unfair incarceration of individuals who 
engage in drug use. With reclassification, people will be making money from these 
substances in a legal way, and the medical research will be more permissible. 
Therefore, individuals who have been jailed for the use of these substances are owed 
special consideration, as I will discuss later. The criminalization of these medicines 
creates huge inequities as certain people have been persecuted for using these  
substances whereas there are others who have access to these substances in clinical 





Implications of Increased ‘Recreational’ Use 
 
 The reclassification of any substance necessitates the consideration of social 
implications – especially when considering Psilocybin, a naturally found compound with 
a very complex history. If Psilocybin is reclassified for therapeutic purposes, we, as a 
society, will need to rethink how we view these naturally occurring psychedelic 
substances and how we view those who choose to use these substances outside of a 
therapeutic context. As with any drug, there will be non-clinical, or ‘recreational’ / 
‘underground,’ use of the substance. For that reason, risk reduction education is 
absolutely crucial, as I will discuss shortly. Before I delve into the implications of 
increased ‘recreational’ use, I will briefly discuss a gripe I have with the term 
‘recreational’ when it comes to Psilocybin use. It is the same issue that Robert Jesse 
brought up while Michael Pollan interviewed Jesse for his book, How to Change Your 
Mind. Jesse explained “[m]aybe we need to reexamine that term. Typically, it is used to 
trivialize an experience.”48 I hope that by this point in my thesis, it is clear that there is 
nothing trivial about Psilocybin, and psychedelics in general. These plant medicines 
lead to deep, meaningful experiences and should be treated with respect and 
reverence. However, due to lack of a better term and general knowledge of this term 
within the substance use space, I will be utilizing it.  
 A societal implication of reclassification is the potential for increased recreational 
use. It is likely the case that if the federal government reclassifies Psilocybin and 
officially states that it does have a medical use, there will be an increased use of 





self-medicating purposes. While this is not necessarily a ‘bad’ thing in my opinion, there 
needs to be proper education and risk reduction. While most know about ‘harm 
reduction,’ I prefer to call it ‘risk reduction’ as I believe the latter term has a much less 
negative connotation and it more accurately acknowledges that there are risks when it 
comes to using Psilocybin without stigmatization of those who choose to use. There will 
always be underground use of substances. And with Psilocybin, a substance that has 
great potential with genuine risks, society needs to be made aware of the risks and 
educated so that people know what they are getting into. This shift in societal thinking is 
imperative to ensure that people remain safe, and risks are minimized in order to help 
people fulfill the potential of their psychedelic experience to heal lasting trauma and 
other mental health woes.  
 There are already some effective risk reduction platforms and outlets, but as 
Psilocybin becomes increasingly mainstream, more attention to risk reduction and 
education will be necessary. As more people explore psychedelics outside of 
supervised, medical contexts, with many of those people having a psychedelic 
experience for the first time, risk reduction is essential. The Zendo Project is an 
example of a ‘risk reduction’ (they use the term ‘harm reduction’) platform which 
“provides professional comprehensive harm reduction education and support for 
communities to help inform and transform difficult psychedelic experiences into 
opportunities for learning and growth.”49 They “envision a world where communities are 
educated, resourced, and engaged in applying harm reduction principles to support 
individuals exploring psychedelic states; recognizing that challenging experiences can 





support principles of (1) safe space; (2) talk through, not down; (3) sitting, not guiding; 
and (4) difficult is not bad.49 A group of researchers also recently, in March 2021, 
published a transtheoretical model for Psychedelic Harm Reduction and Integration 
(PHRI) in clinical practice.50 In the model, Gorman et al. combine elements from harm 
reduction psychotherapy and psychedelic-assisted psychotherapy. The PHRI model 
“represents a shift away from assessment limited to untoward outcomes of psychedelic 
use and abstinence-based addiction treatment paradigms and toward a stance of 
compassionate, destigmatizing acceptance of patients’ choices.”50 Another example of a 
risk reduction program is the Fireside Project, a non-profit psychedelic peer support line 
that provides free and confidential peer support to anyone either currently experiencing 
a crisis during a psychedelic journey or anyone who needs support in processing a past 
psychedelic journey.51 Such peer risk reduction practices must be continued and 
expanded so that the education and support is accessible to all.  
 
Distributive Justice and Fairness Issues 
  
 When it comes to any sort of therapeutic medicine, distributive justice issues 
must be addressed. This is especially the case with Psilocybin, given the nature of the 
transformative experience. There need to be specific sets and settings for these 
therapies to take place in controlled therapeutic environments, and the Psilocybin 
experience lasts around six hours. So, there needs to be dedicated staffing and 
locations, which means these therapies may end up being costly. The costs of these 





to offer equitable access. I believe that eventually, multiple avenues of accessibility 
might be needed to most effectively harness the powers of this plant medicine and 
make it accessible to everyone who truly needs it.  
 As Psilocybin becomes more mainstream, fairness issues also arise. This 
substance was originally found naturally in certain species of mushrooms and has been 
used by various indigenous peoples for cultural, religious, and spiritual practices for 
centuries. As the first users of these plant medicines, something is definitely owed to 
these indigenous populations and they must have a seat at the table in the psychedelic 
space. Furthermore, people of color have been constantly excluded from psychedelic 
research and the benefits it provides.52 It is essential to ensure that people of color and 
descendants of indigenous cultures are included in the research and practice of 
psychedelic therapy. 
The guidelines proposed by Johnson et al. in 2008, mentioned earlier, do indeed 
incorporate some of the important teachings from indigenous cultures to remain 
respectful of these populations as well as to not exploit their sacraments.41 They discuss 
the need for “structured use (expressed as ritual in indigenous use), restrictions on use 
including the need for guidance, and appreciation of [psychedelics’] powerful 
psychological effects (expressed as reverence in indigenous use).”41 There needs to be 
a shift from a sense of ‘ownership’ to ‘stewardship’ when it comes to plant medicines 
and the knowledge that experienced individuals are sharing. Companies should not be 
filing patents on plant medicines as no one truly owns them; individuals are forwarding 
their knowledge about the medicine through history. To that extent, we must tread 





As for-profit companies begin to consider the business of psychedelic medicine, 
their intentions need to be examined. At the end of the day, they are entering this 
medicinal space to profit from the increased use of psychedelics, which may not be very 
conducive to stewarding a plant medicine as potent as Psilocybin. When we look at the 
history of for-profit companies in the medicinal space, the story of the opioid epidemic 
and the societal exploitation should serve as a cautionary tale.53 We cannot let the 
same thing happen with psychedelics. It is also obvious that the supply-demand 
relationship is skewed when there are economic advantages to those who create and 
control the supply. These benefits lead those who control the supply to develop quite a 
strong interest in fostering and increasing the demand, which is ethically questionable. 
While I cannot delve into this relationship in depth as it is deserving of a thesis in and of 
itself, there needs to be special safeguards and protections in place to prevent the 
marketization of psychedelics to the point where people are exploiting others and 
‘selling’ medicine for their own personal gain. This would be in conflict with the 
commitment to indigenous cultures that have shared the knowledge of this plant 
medicine with the Western medicine community. While this is a major downfall of big 
pharmaceutical companies, they are going to continue to exist nonetheless, and the 
business model does have some positive aspects. I posit that there needs to be an 
integration of the positive aspects of the business model and community-based, non-
profit organizations. The future of medicine should not look like the past with what 
happened to start the opioid epidemic. For-profit companies are trying to make the most 
profit rather than help people heal; this dissonance between the intention of the ‘healer’ 





breeding ground for exploitation. We need to tap into the various sources of knowledge 
that different populations have (e.g., people who have been incarcerated for 
psychedelic use and indigenous communities) to create a collaborative and supportive 
network of healers and optimize access for the people who need these medicines. 
 Finally, lessons learned from another plant medicine, cannabis, can be applied to 
guide the entrance of psychedelic medicine into society. As Marks briefly mentioned, 
“[r]ecent state level [cannabis] reform efforts could serve as a roadmap for amending 
the laws governing psychedelics. Ultimately, creative solutions that promote 
collaboration between state and federal government may be most likely to succeed.”47 
We need to be wary of the capitalistic commercialization that leads to hyper-competitive 
markets. However, we must be cautious with following the cannabis model precisely 
because of the different experience that psychedelics provide. Rather than sending 
people home with their medications, as with cannabis, psychedelic therapy takes place 
in a specific setting for a certain amount of time.54 Psychedelics have the opportunity to 
become a new model for the rest of the pharmaceutical world, as I will conclude with, 













Psilocybin as a Therapeutic Tool 
  
 As I have demonstrated, Psilocybin is an extremely promising treatment option, 
especially for people who have been unresponsive to current mental health therapies. 
Our current mental health paradigms have been unable to adequately address mental 
health illnesses as they continue to trouble society. We need ‘every tool in our toolbox,’ 
and Psilocybin is the therapeutic tool we need right now. Scientifically speaking, 
Psilocybin ought to be reclassified as it does not have a high potential for abuse, it is not 
addictive, and it is medically useful in controlled settings. Yet, people object on the 
grounds that there remain ethical and societal issues associated with reclassification.  
 I have illustrated the safeguards that are in place and should be in place in order 
to adequately address the ethical and societal issues of integrating Psilocybin into 
standard therapeutic practices. By downregulating one’s DMN, Psilocybin enables one 
to break free of the constraints of their mental health illness to heal the root cause. 
Psilocybin helps one interact with their trauma in a safe, controlled setting with 
experienced monitors to help overcome their trauma rather than just masking the 
symptoms of it. I argue that Psilocybin experiences actually put one more in touch with 
their personal identity and expand one’s autonomy rather than inhibit it; Psilocybin puts 
patients in a position to heal themselves. With the proper safety measures taken, 





minimized, are far outweighed by the benefits, especially during a time of societal 
mental health crisis.  
 
Societal Shift in Perception of Psychedelics 
  
We need to change our perception of drugs in general, but especially plant 
medicines such as Psilocybin. As asserted, drugs are not inherently ‘good’ or ‘bad’ – 
they are just chemicals humans use, whose outcomes are dependent on intent and 
circumstance. The war on drugs is extremely outdated and treating drug problems as 
crimes rather than illnesses is unethical and unnecessarily stigmatizing. The 
decriminalization model has been used quite successfully in Portugal as it has shown 
you can reduce harmful drug intake by decriminalizing drugs.55–57 Portugal 
decriminalized all drugs beginning July 1, 2001, and:  
[b]y freeing its citizens from the fear of prosecution and imprisonment for drug 
usage…has dramatically improved its ability to encourage drug addicts to avail 
themselves of treatment. The resources that were previously devoted to 
prosecuting and imprisoning drug addicts are now available to provide treatment 
programs to addicts. Those developments, along with Portugal’s shift to a harm-
reduction approach, have dramatically improved drug- related social ills, 
including drug-caused mortalities and drug-related disease transmission.58 
The success of Portugal even influenced Oregon to become the first state to 
decriminalize all drugs with the passing of Measure 110 in November of 2020.54,59 





and safety over punishment, and reduce the stigma associated with drug use.60 
Furthermore, a study conducted by researchers at the University of Alabama at 
Birmingham suggests that psychedelic therapies could actually reduce criminal 
behavior.61 A recent study published in The New England Journal of Medicine, the first 
of its kind, compared Psilocybin to Escitalopram for depression: researchers showed 
that Psilocybin and Escitalopram were just as effective at treating the primary outcomes 
of depression, and that “[s]econdary outcomes generally favored Psilocybin over 
Escitalopram, but the analyses of these outcomes lacked correction for multiple 
comparisons” and therefore further studies are needed.62 A societal shift is crucial for 
the advancement of plant medicines for healing purposes. 
 
Plant Medicines & the Future 
 
 “During the 1950s, psychedelic psychiatry promised consciousness-raising, 
identity-changing therapy within a medically sanctioned and scientifically rigorous 
environment.”7 As we now have even more advanced technological and scientific 
practices and understandings, we need to combine our concept of Western medicine 
with integrative, natural, plant medicines. Psilocybin provides the opportunity for us to 
see ourselves as one organism, which may be helpful when it comes to the accessibility 
of plant medicines. Maybe we should create a new model of having a shared resource 
pool of natural plant medicines that is aimed at environmental and traditional 
conservation. Our biological and scientific advances have allowed us to create 





proceeds need to be redistributed to the conservation of plants, cultures, and the aid of 
those who have been negatively impacted by the criminalization of psychedelics. This 
will allow us to kickstart a regenerative economy – one that is sustainable for future 
generations and is furthered through collaboration and equity – through the use of plant 
medicines which could lead to more access and less exploitation. While these 
substances may have much more potential beyond healing in therapeutic contexts, in 
order for the general public to begin to understand that, psychedelics need to be first 
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